Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]

Lung Cancer. 2024 Jul:193:107852. doi: 10.1016/j.lungcan.2024.107852. Epub 2024 Jun 17.
No abstract available

Publication types

  • Published Erratum